Aviron FluMist "complete response"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA issues "complete response" letter for Aviron's Flumist for prevention of influenza in healthy children and adults. The letter, received by the firm Aug. 31, requests information "regarding clinical and manufacturing data." Aviron does not expect to conduct additional clinical trials and still expects a 2002 FluMist launch. During a July 30 analysts meeting, Aviron said the company will submit a pediatric safety study in Kaiser Permanente outpatients by the end of the year to FDA, and would be willing to "raise the lower age threshold for the indication" if it would hasten approval. At the Vaccines and Related Biological Products Advisory Committee review July 26-27, concern was expressed about the limited amount of data in children aged 12-15 months and about insufficient safety data
You may also be interested in...
Stalemate Over Virtual Audits In EU As Commission Tells TEAM-NB To Back Off
Notified bodies’ efforts to enhance a harmonized approach to remote audits have failed, raising questions about whether there is any avenue left to get vital devices certified by the 26 May EU MDR deadline.
Amneal’s Generics Business Reinvigorated By New Launches
As Amneal’s generics segment sees significant growth, the company has revealed plans to launch new products and expand in new markets. “We are extremely proud of the progress our company has made since we re-joined as leaders of Amneal,” said Chirag and Chintu Patel, co-CEOs of Amneal.
Medtech SMEs See Opportunities In UK Budget Of Few Surprises
Schemes and funding to support growth in the life sciences and medtech sectors featured in the UK government’s spring budget on 3 March.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: